Last Updated on March 3, 2021 by The Health Master
Global pharma major Lupin Limited announced the launch of the United States Food and Drug Administration (USFDA) approved penicillamine tablets USP, 250 mg.
Penicillamine tablets USP, 250 mg, are the generic equivalent of Depen tablets, 250 mg, of Mylan Specialty, L.P..
This drug is indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Penicillamine tablets USP, 250 mg had estimated annual sales of US$ 5 million in the US, according to IQVIA MAT December 2020.
Also read:
NATCO launches Epilepsy Tablets in India
ICPA launches antibiotic for Dental treatment
Zydus Cadila gets USFDA nod for Anti Depressant drug
Granules gets USFDA nod for Acetaminophen, Aspirin and Caffeine tablets
Strides gets USFDA Yes for Ibuprofen OTC Oral Suspension
Sun Pharma to launch entire range of Epilepsy treatment drug in India
